• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Complement-ARIE: Catalyzing the Development and Adoption of New Approach Methodologies.补体-ARIE:催化新方法学的开发与应用
NAM J. 2025;1. doi: 10.1016/j.namjnl.2025.100026. Epub 2025 May 17.
2
Ways to broaden the awareness, consideration and adoption of new approach methodologies (NAMs).拓宽对新方法学(NAMs)的认识、考量及采用的方法。
ALTEX. 2025 Jun 26. doi: 10.14573/altex.2505281.
3
Fabricating mice and dementia: opening up relations in multi-species research制造小鼠与痴呆症:开启多物种研究中的关联
4
Developing a role for patients and the public in the implementation of health and social care research evidence into practice: the PIPER study (Pathways to Implementation for Public Engagement in Research) realist evaluation protocol.让患者和公众在将健康与社会护理研究证据转化为实践中发挥作用:PIPER研究(公众参与研究的实施途径)的实在论评价方案。
Res Involv Engagem. 2025 Jul 14;11(1):80. doi: 10.1186/s40900-025-00728-w.
5
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.成年自闭症患者的就业生活经历:系统检索与综述
Autism Adulthood. 2024 Dec 2;6(4):495-509. doi: 10.1089/aut.2022.0114. eCollection 2024 Dec.
6
Short-Term Memory Impairment短期记忆障碍
7
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.胰岛素治疗的卫生经济学:我们如何应对不断增长的需求、成本、不平等现象以及实现最佳治疗效果的障碍。
Diabetes Obes Metab. 2025 Jul;27 Suppl 5(Suppl 5):24-35. doi: 10.1111/dom.16488. Epub 2025 Jun 4.
8
Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development.制药行业(IQ MPS附属机构)关于动物微生理系统与药物研发中的3R原则研讨会的相关考量。
ALTEX. 2025 Apr 11. doi: 10.14573/altex.2503261.
9
Animal-free safety assessment of chemicals: an innovation system perspective.化学品的无动物安全评估:创新系统视角
Arch Toxicol. 2025 Jan;99(1):43-56. doi: 10.1007/s00204-024-03878-0. Epub 2024 Oct 4.
10
How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis.疾病轨迹的生活经历、治疗负担和社会不平等如何影响服务使用者和照顾者参与健康和社会护理:一项基于理论的定性证据综合分析
Health Soc Care Deliv Res. 2025 Jun;13(24):1-120. doi: 10.3310/HGTQ8159.

本文引用的文献

1
Artificial intelligence (AI)-it's the end of the tox as we know it (and I feel fine).人工智能(AI)——这是我们所知道的毒理学的终结(我感觉很好)。
Arch Toxicol. 2024 Mar;98(3):735-754. doi: 10.1007/s00204-023-03666-2. Epub 2024 Jan 20.
2
Rational design of supramolecular self-assembly sensor for living cell imaging of HDAC1 and its application in high-throughput screening.超分子自组装传感器用于活细胞中 HDAC1 的成像的合理设计及其在高通量筛选中的应用。
Biosens Bioelectron. 2023 Dec 15;242:115716. doi: 10.1016/j.bios.2023.115716. Epub 2023 Oct 6.
3
Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.患者来源的类器官培养在卵巢上皮性癌中的应用——技术、应用和未来展望。
Cancer Med. 2023 Oct;12(19):19714-19731. doi: 10.1002/cam4.6521. Epub 2023 Sep 30.
4
Biomedical generative pre-trained based transformer language model for age-related disease target discovery.基于生物医学生成式预训练的转化器语言模型在与年龄相关疾病靶点发现中的应用。
Aging (Albany NY). 2023 Sep 22;15(18):9293-9309. doi: 10.18632/aging.205055.
5
Recent advances in measurement of metabolic clearance, metabolite profile and reaction phenotyping of low clearance compounds.低清除率化合物的代谢清除率测量、代谢物谱分析及反应表型分析的最新进展。
Expert Opin Drug Discov. 2023 Jul-Dec;18(11):1209-1219. doi: 10.1080/17460441.2023.2238606. Epub 2023 Aug 1.
6
Engineering prostate cancer in vitro: what does it take?体外构建前列腺癌模型:需要做些什么?
Oncogene. 2023 Aug;42(32):2417-2427. doi: 10.1038/s41388-023-02776-6. Epub 2023 Jul 12.
7
Quantitative proteomic studies addressing unmet clinical needs in sarcoma.针对肉瘤未满足临床需求的定量蛋白质组学研究。
Front Oncol. 2023 May 1;13:1126736. doi: 10.3389/fonc.2023.1126736. eCollection 2023.
8
High-throughput AR dimerization assay identifies androgen disrupting chemicals and metabolites.高通量雄激素受体二聚化检测可识别雄激素干扰化学物质和代谢物。
Front Toxicol. 2023 Apr 4;5:1134783. doi: 10.3389/ftox.2023.1134783. eCollection 2023.
9
Heart-on-a-chip platforms and biosensor integration for disease modeling and phenotypic drug screening.芯片上的心脏平台和生物传感器集成用于疾病建模和表型药物筛选。
Biosens Bioelectron. 2023 Jan 15;220:114840. doi: 10.1016/j.bios.2022.114840. Epub 2022 Oct 25.
10
Why 90% of clinical drug development fails and how to improve it?为什么90%的临床药物研发会失败以及如何改进?
Acta Pharm Sin B. 2022 Jul;12(7):3049-3062. doi: 10.1016/j.apsb.2022.02.002. Epub 2022 Feb 11.

补体-ARIE:催化新方法学的开发与应用

Complement-ARIE: Catalyzing the Development and Adoption of New Approach Methodologies.

作者信息

Sunderic Kristifor, Wright Andrew M, Kleinstreuer Nicole, Ledbetter Victoria, Milora Katelynn A, Happel Christine, Shaughnessy Daniel, Johnstone Chariz P, Casco Daniel Anthony, Macioce Nikeya, Marzec Jacqui, Kano Kristin, Ochocinska Margaret J, Tagle Danilo A

机构信息

National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.

Office of the Director, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

NAM J. 2025;1. doi: 10.1016/j.namjnl.2025.100026. Epub 2025 May 17.

DOI:10.1016/j.namjnl.2025.100026
PMID:40765716
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12320934/
Abstract

New approach methodologies (NAMs) are proving to be invaluable tools in basic and clinical research to better understand human health and disease, elucidate mechanisms, and study the efficacy and toxicity of novel therapeutics that can improve upon and complement animal-based methodologies. Over the last 15 years, the National Institutes of Health (NIH) has increased investment in NAMs, including in chemico, in silico, and in vitro approaches, such as cell-free assay systems, digital twins, and microphysiological systems (MPS). To further catalyze and innovate the use of NAMs, the NIH Common Fund has initiated a new program, Complement Animal Research In Experimentation (Complement-ARIE), which aims to pioneer the development, standardization, validation, and regulatory use of combinatorial NAMs that will more accurately model human biology and disease states. This program specifically aims to 1) better model human health and disease differences in outcomes across populations, 2) develop NAMs that can provide insights into specific biological processes or disease states, 3) validate mature NAMs to support regulatory use and standardization, and 4) complement traditional animal models to make research more efficient and effective. To inform the implementation of Complement-ARIE, the NIH organized strategic planning activities including an inter-agency retreat, public listening sessions, scientific literature landscape analysis, and a challenge prize. Here we discuss the goals and findings of these activities, and how these results helped identify and address scientific and operational opportunities and roadblocks for implementation of the program towards broader acceptance and impact of NAMs. We anticipate these new methods and approaches could transform the way we do basic, translational, and clinical sciences.

摘要

新方法学(NAMs)已被证明是基础研究和临床研究中非常有价值的工具,有助于更好地理解人类健康与疾病、阐明机制,并研究新型疗法的疗效和毒性,这些疗法能够改进并补充基于动物的方法学。在过去15年里,美国国立卫生研究院(NIH)增加了对NAMs的投资,包括化学、计算机模拟和体外方法,如无细胞检测系统、数字孪生和微生理系统(MPS)。为了进一步推动和创新NAMs的应用,NIH共同基金启动了一个新项目,即实验中补充动物研究(Complement-ARIE),旨在开创组合式NAMs的开发、标准化、验证及监管应用,从而更准确地模拟人类生物学和疾病状态。该项目具体目标包括:1)更好地模拟不同人群在健康和疾病结果方面的差异;2)开发能够深入了解特定生物过程或疾病状态的NAMs;3)验证成熟的NAMs以支持监管应用和标准化;4)补充传统动物模型,使研究更高效、更有效。为指导Complement-ARIE的实施,NIH组织了战略规划活动,包括跨部门务虚会、公众听证会、科学文献综述分析以及一项挑战奖。在此,我们讨论这些活动的目标和结果,以及这些结果如何帮助识别和解决科学及操作方面的机遇与障碍,以推动该项目的实施,使NAMs得到更广泛的接受和产生更大影响。我们预计这些新方法和途径可能会改变我们开展基础科学、转化科学和临床科学研究的方式。